MUC2 and inflammatory bowel disease: The fact that both treatments led to significant improvements in MUC2 and tight junction protein expressions points to their potential utility in clinical settings, particularly for conditions characterized by barrier dysfunction, such as inflammatory bowel diseases (IBD).